EMBC
Embecta Corp. (NASDAQ)
Healthcare — Medical Instruments & Supplies
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
None
2 analysts
$3.36
+$0.10 (+3.07%)
Target:
$4.00
(19.0%)
Sign in to add EMBC to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $199.34M |
| P/E Ratio (TTM) | 1.78 |
| Forward P/E | 1.93 |
| EPS (TTM) | $1.89 |
| Dividend Yield | 13.67% |
| Profit Margin | 10.73% |
| Revenue Growth | -14.40% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $4.00 |
| Analysts | 2 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 56.4 |
| Beta | 0.81 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $15.55 |
| 52-Week Low | $2.77 |
| 50-Day Avg | $4.45 |
| 200-Day Avg | $9.98 |
| Avg Volume | $2.39M |
| Volume | $2.02M |
Performance Analysis
BULLISHEMBC shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($2.77), which could present a value opportunity.
+
RSI at 56.4 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
P/E of 1.8 suggests the stock may be undervalued.
-
Revenue declined 14.4% year-over-year.
~
Wall Street consensus is "none" from 2 analysts.
+
Average analyst target of $4.00 implies 19.0% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:07 UTC
Back to Screener Export Report